Arvinas
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 445
- Market Cap
- $1.7B
- Website
- http://www.arvinas.com
- Introduction
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men...
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Arvinas Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT06393738
- Locations
- 🇪🇸
Clinical Trial Site, Madrid, Spain
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Arvinas Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05549505
- Locations
- 🇪🇸
Clinical Trial Site, Zaragoza, Spain
© Copyright 2024. All Rights Reserved by MedPath